A theoretical insight into selectivity of inhibitors toward two domains of bromodomain‐containing protein 4 using molecular dynamics simulations. (10th December 2017)

• Record Type: Journal Article
• Authors: Su, Jing; Liu, Xinguo; Zhang, Shaolong; Yan, Fangfang; Zhang, Qinggang; Chen, Jianzhong
• Is Part Of: Chemical biology & drug design. Volume 91:Number 3(2018)
• Page Start: 828
• Page End: 840
• Publication Date: 2017-12-10
• Subjects: alanine scanning -- BD1 and BD2 domains -- bromodomain‐containing protein 4 -- MM‐PBSA -- principal component analysis; Drugs -- Design -- Periodicals; Pharmaceutical chemistry -- Periodicals; Biochemistry -- Periodicals; 615.19005
• DOI: 10.1111/cbdd.13148
• Languages: English
• ISSNs: 1747-0277

Abstract

Abstract : Bromodomains (BRDs) have been an attractive candidate for development of efficient inhibitors toward gene transcription. Molecular dynamics (MD) simulations followed by principal component (PC) analysis were performed to investigate binding selectivity of inhibitors RVX297, BSP, JQ1, SF2523, and CPD2 toward two domains (BD1 and BD2) of bromodomain‐containing protein 4 (BRD4). The results show that inhibitor bindings exert different effect on motions of the BC‐loops in BD1 and BD2. The rank of binding free energies calculated using molecular mechanics Poisson–Boltzmann surface area (MM‐PBSA) method agrees with the one determined by experiment. The results also suggest that the binding ability of RVX297, BSP, and JQ1 to BD2 is stronger than that of them to BD1, while the binding ability of SF2523 to BD2 is obviously weaker than that of SF2523 to BD1. Alanine mutation calculations and the calculated inhibitor–residue interaction spectrum prove that the current five inhibitors have obvious binding selectivity toward BD1 and BD2. This study is not only helpful for further understanding the differences in internal dynamics of BD1 and BD2 caused by inhibitor bindings, but also can theoretically contribute significant guidance to designs of effective and high selective anticancer drugs targeting BD1 and BD2 in BRD4. Abstract : According to the cross‐correlation analysis and PC analysis, the inhibitor bindings generate different influence on motions of the BC‐loop in the two domains BD1 and BD2 of BRD4. Alanine mutation calculations and the calculated inhibitor–residue interaction spectrum prove that the current five inhibitors have obvious binding selectivity toward BD1 and BD2.